- Home
- TWFG vs SIGA Comparison
TWFG vs SIGA Comparison
Compare TWFG & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWFG
- SIGA
- Stock Information
- Founded
- TWFG 2001
- SIGA 1995
- Country
- TWFG United States
- SIGA United States
- Employees
- TWFG N/A
- SIGA N/A
- Industry
- TWFG
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- TWFG
- SIGA Health Care
- Exchange
- TWFG NYSE
- SIGA Nasdaq
- Market Cap
- TWFG 530.3M
- SIGA 422.9M
- IPO Year
- TWFG 2024
- SIGA 1997
- Fundamental
- Price
- TWFG $35.37
- SIGA $6.69
- Analyst Decision
- TWFG Buy
- SIGA
- Analyst Count
- TWFG 8
- SIGA 0
- Target Price
- TWFG $33.71
- SIGA N/A
- AVG Volume (30 Days)
- TWFG 122.5K
- SIGA 405.0K
- Earning Date
- TWFG 08-26-2025
- SIGA 07-31-2025
- Dividend Yield
- TWFG N/A
- SIGA 8.97%
- EPS Growth
- TWFG N/A
- SIGA N/A
- EPS
- TWFG N/A
- SIGA 0.67
- Revenue
- TWFG $211,440,000.00
- SIGA $120,330,310.00
- Revenue This Year
- TWFG $23.90
- SIGA N/A
- Revenue Next Year
- TWFG $22.60
- SIGA $95.31
- P/E Ratio
- TWFG N/A
- SIGA $9.97
- Revenue Growth
- TWFG 18.57
- SIGA N/A
- 52 Week Low
- TWFG $21.31
- SIGA $4.95
- 52 Week High
- TWFG $36.85
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- TWFG N/A
- SIGA 62.39
- Support Level
- TWFG N/A
- SIGA $6.34
- Resistance Level
- TWFG N/A
- SIGA $6.81
- Average True Range (ATR)
- TWFG 0.00
- SIGA 0.26
- MACD
- TWFG 0.00
- SIGA 0.02
- Stochastic Oscillator
- TWFG 0.00
- SIGA 85.00
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.